TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 18nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 33nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 42nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 44nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 49nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 52nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 62nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 68nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 80nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 90nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 115nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 130nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 270nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: 280nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of XIAP using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 301nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: 365nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of XIAP using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 450nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 593nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 740nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 740nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 780nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 790nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 1.69E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 1.99E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 3.36E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 3.38E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 3.89E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 5.02E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataIC50: 5.75E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of cIAP1 using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: >8.00E+3nMAssay Description:Antagonist activity at GST-tagged BIR3 domain of XIAP using AbuRPFK-5FAM after 20 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 156nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 164nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 158nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 117nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 71nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 60nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 68nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 60nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: 300nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Astrazeneca R&D Boston
Curated by ChEMBL
Astrazeneca R&D Boston
Curated by ChEMBL
Affinity DataEC50: >370nMAssay Description:Antagonist activity at cIAP1 in human MDA-MB-231 cells assessed as cIAP1 degradation after 1 hr by ELISAMore data for this Ligand-Target Pair